MedPath

VR-assisted Curriculum on Depression for Stigma Reduction

Not Applicable
Conditions
Control
Behavior
Interventions
Device: Virtual Reality
Device: Brochure
Device: Standard Video Control
Registration Number
NCT03912597
Lead Sponsor
Yale-NUS College
Brief Summary

Two randomised controlled trials will be conducted to evaluate a virtual reality (VR) simulation designed to reduce stigma against depression. Qualitative interviews will also be carried out to evaluate the VR simulation.

Detailed Description

The investigators examine the impact of a VR-assisted curriculum on stigma reduction towards individuals with depression. This is done through the development and evaluation of a VR-assisted curriculum that promotes stigma reduction towards depression among tertiary-aged students. Collection of data will provide insights about the effectiveness of VR's immersive quality in enhancing stigma reduction skills through measures of attitudes, beliefs and knowledge about depression. In the first study, VR is compared with traditional pamphlets in an information sharing booth about depression. In the second study, participants attend a 30-min session where they undergo an educational curriculum with either a VR or standard video as adjunctive tools.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Tertiary students from NUS and Yale-NUS only
Exclusion Criteria
  • History of medical or psychiatric disorder; History of motion sickness, dizziness or epilepsy; (For reliability and safety of heart-rate monitoring) Tattoos near the wrist and/or nickel or acrylate allergies

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Virtual Reality [A]Virtual RealityParticipants watch a 4-minute virtual reality video, on top of reading a brochure, then answer post-intervention questionnaires.
Standard Video Control [B]BrochureParticipants watch a 4-minute standard video. After which, using a video, a discussion of the video will be facilitated for participants to contextualise and understand the video better. Then, participants answer post-intervention questionnaires.
Virtual Reality [B]BrochureParticipants answer pre-questionnaires, then watch a 4-minute virtual reality video. After which, using a video, a discussion of the video will be facilitated for participants to contextualise and understand the video better. Then, participants answer post-intervention questionnaires.
Virtual Reality [A]BrochureParticipants watch a 4-minute virtual reality video, on top of reading a brochure, then answer post-intervention questionnaires.
Virtual Reality [B]Virtual RealityParticipants answer pre-questionnaires, then watch a 4-minute virtual reality video. After which, using a video, a discussion of the video will be facilitated for participants to contextualise and understand the video better. Then, participants answer post-intervention questionnaires.
Brochure Waitlist Control [A]BrochureParticipants read an informational brochure about depression, then answer post-intervention questionnaires. After that, they will be given a chance to watch the VR video at the end of their participation session.
Standard Video Control [B]Standard Video ControlParticipants watch a 4-minute standard video. After which, using a video, a discussion of the video will be facilitated for participants to contextualise and understand the video better. Then, participants answer post-intervention questionnaires.
Primary Outcome Measures
NameTimeMethod
Knowledge about depression2 minutes

A Depression Literacy measure will be used to assess participants' understanding and knowledge of depression.

Video Enjoyment1 minute

In the VR condition, enjoyment of the VR simulation will be assessed through five items on a video enjoyment questionnaire created by the researchers, that includes items such as "I found the video interesting" and "The video made me more interested in the topic" on a visual analog scale. The scale was anchored between 0 indicating "Strongly Disagree" to 10 indicating "Strongly Agree".

Video Presence1 minute

Presence felt in the VR simulation will be assessed through four items on a video presence questionnaire, that includes items such as "How aware were you of events happening in your actual surroundings outside of the video?" and "How strong was your sense of 'being there' in the video environment?" on a visual analog scale. The questions were adapted from the original Presence Questionnaire by Witmer and Singer (1998) that outlined four sub-factors of control, sensory, distraction and realism; items in our questionnaire were carefully selected to represent all of the factors. The scale ranged from 0 indicating "Not At All" to 10 indicating "Very Much So".

Stigmatising attitudes towards depression5 minutes

Stigmatising attitudes refer to the opinions that one has towards persons with depression, and how they would interact with these group of people. This will be measured using an adapted version of the Attribution Questionnaire-27.

Stigmatising beliefs towards depression2 minutes

The extent of agreement with negative beliefs and stereotypes about depression will be adapted from the 10-item agreement sub-scale of the Self-Stigma of Mental Illness Scale.

Secondary Outcome Measures
NameTimeMethod
Heart rate live tracking4 minutes

Changes in heart rate, assessed live during the video viewing duration, will be measured as a physiological measure of user experience.

Qualitative feedback about VR video10 minutes

Participants will be invited to give feedback on their VR experience. Questions in the qualitative interview will address (1) their thoughts on mental health awareness amongst the public, (2) their experience watching the VR simulation and (3) reasons for stopping, or not, at similar mental health booths with VR simulations in the future.

Affect (PANAS)3 minutes

Participants' mood will be assessed using the Positive and Negative Affect Scale (PANAS) as a secondary measure of user experience with the respective videos. The PANAS consists of two 10-item subscales assessing positive and negative affect, and is rated on a 5-point scale ranging from 1 representing "Very Slightly or Not at All" to 5 representing "Extremely".

Trial Locations

Locations (1)

Yale-NUS College

🇸🇬

Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath